8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2019

ViewRay, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37725	42-1777485
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2 Thermo Fisher Way Oakwood Village, OH		44146
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (440) 703-3210

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Item 2.02 Results of Operations and Financial Conditions.

On January 7, 2019, ViewRay, Inc. (“ViewRay”) issued a press release announcing preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 7.01 Regulation FD Disclosure.

Spokespersons of ViewRay, Inc. (“ViewRay”) plan to present the information in the presentation attached hereto as Exhibit 99.2 at the 37^th Annual J.P. Morgan Healthcare Conference on January 7, 2019.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that is intended to be considered in the context of more complete information included in ViewRay’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public announcements that ViewRay has made and may make from time to time by press release or otherwise. ViewRay undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled “Disclaimer” in Exhibit 99.2 attached hereto.

The information in this Item 7.01 of this Form 8-K and the Exhibit 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits

(d)    Exhibits.

Exhibit     Number	Description
99.1	Press Release dated January 7, 2019.
99.2	J.P. Morgan Healthcare Conference Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2019		ViewRay, Inc.
	By:	/s/ Robert McCormack
		Robert McCormack
		Senior Vice President and General Counsel

EX-99.1

Exhibit 99.1

ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results

CLEVELAND, January 7, 2019 — ViewRay, Inc. (Nasdaq: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change.

Selected Fourth Quarter and Full Year 2018 Preliminary Highlights:

• Recognized 3 revenue units and 1 system upgrade in the fourth quarter of 2018. This resulted in total fourth quarter 2018 revenue of approximately $21 million, compared to fourth quarter 2017 revenue of $19.9 million, primarily from four revenue units.

• Received 8 new orders for MRIdian systems totaling approximately $49 million in the fourth quarter of 2018, compared to orders totaling $34 million in the fourth quarter of 2017.

• Full year 2018 revenue of approximately $81 million, primarily from 13 revenue units and 2 system upgrades, compared to 2017 revenue of approximately $34.0 million, primarily from 6 MRIdian systems.

• Backlog as of December 31, 2018 grew to approximately $212 million.

• Cash and cash equivalents were approximately $167 million as of December 31, 2018.

“I am pleased with our solid fourth quarter results. We made significant advancements in operational execution, our innovation pipeline, clinical data and training, and our US commercial team is now fully in place,” said Scott Drake, President and CEO. “During the quarter our backlog grew to $212 million, and we removed three systems. While we will continue to review the backlog each quarter, our recent thorough review is now complete.”

Financial guidance for 2019 will be provided on the company’s fourth quarter earnings conference call later this year.

About ViewRay

ViewRay^®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian^® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades and installations, ViewRay’s financial guidance for the full year 2018 and ViewRay’s conference call to discuss its third quarter and year to date results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay’s products, the ability to convert backlog into revenue, and the timing of delivery of ViewRay’s products, the timing, results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business in general, see ViewRay’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and its 2018 Quarterly Reports on Form 10-Q, as updated periodically with

the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Investor Relations:

Michaella Gallina

Sr. Director, Investor Relations and Communications

ViewRay, Inc.

1-844-MRIdian (674-3426)

Email: investors@viewray.com

Media Enquiries:

Karen Hackstaff

Senior Director, Downstream Marketing

ViewRay, Inc.

Phone: +1 408-242-2994

Email: media@viewray.com

EX-99.2

Exhibit 99.2 A Giant Leap in Cancer Therapy Innovation J.P. Morgan Healthcare Conference January 2019  1Exhibit 99.2 A Giant Leap in Cancer Therapy Innovation J.P. Morgan Healthcare Conference January 2019 1

Disclaimer FORWARD‐LOOKING STATEMENTS This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only.  The material is  given in conjunction with an oral  presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the  company,” “we,” “us” and “our” refer to ViewRay,  Inc.  Except for historical information, ViewRay’s written and accompanying oral presentation may contain forward‐looking statements, including statements  about the overall  industry, including but not limited to: our current expectations of the market; growth drivers; future trends; demand for radiation oncology  products and features; and  innovation and growth opportunities. Forward‐looking statements also include, but are not limited to, statements about ViewRay’s: future orders;  backlog or earnings growth;  preliminary fourth quarter and full year 2018 financial results; future financial results; and market acceptance of ViewRay’s existing products, future products or technology.  Words such as “could,” “anticipates,” “expects,” “outlook,” “intends,” “plans,” “believes,”  “seeks,” “vision,” “estimates,” “may,” “will,” “future,” “horizon,” “aiming,” “driving,”  “target” (or variations of them) and similar statements, are forward‐looking statements. These types of statements express management’s  beliefs based on the information  available to us as of the date of this presentation, are subject to change and are not guarantees of future performance.  Forward‐looking statements involve risks, uncertainties  and assumptions that are difficult to predict and could cause ViewRay’s results to differ materially from those presented. These risks, uncertainties and assumptions include,  but are not limited to, changes in: the regulatory environment; global economics; trade compliance requirements, duties or tariffs; third‐party  reimbursement levels; currency  exchange rates; taxation, healthcare law, and product clearance requirements, as well as those related to: adverse publicity about ViewRay and  our products; our reliance on  sole or limited source suppliers; our ability to commercialize our products successfully; the impact of competitive products and pricing, and all other risks listed from time to  time in the company’s filings with the Securities and Exchange Commission, which are incorporated into this Forward‐Looking Statements  disclosure by this reference. We do  not assume any obligation to update or revise the forward‐looking statements in ViewRay’s written or oral presentation, whether based on  future events, new or additional  information or otherwise.  ViewRay’s written and oral presentation does not constitute an offer to sell or the solicitation of an  offer to buy, securities. MEDICAL ADVICE DISCLAIMER ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches.  Individual results may vary. 2Disclaimer FORWARD‐LOOKING STATEMENTS This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “we,” “us” and “our” refer to ViewRay, Inc. Except for historical information, ViewRay’s written and accompanying oral presentation may contain forward‐looking statements, including statements about the overall industry, including but not limited to: our current expectations of the market; growth drivers; future trends; demand for radiation oncology products and features; and innovation and growth opportunities. Forward‐looking statements also include, but are not limited to, statements about ViewRay’s: future orders; backlog or earnings growth; preliminary fourth quarter and full year 2018 financial results; future financial results; and market acceptance of ViewRay’s existing products, future products or technology. Words such as “could,” “anticipates,” “expects,” “outlook,” “intends,” “plans,” “believes,” “seeks,” “vision,” “estimates,” “may,” “will,” “future,” “horizon,” “aiming,” “driving,” “target” (or variations of them) and similar statements, are forward‐looking statements. These types of statements express management’s beliefs based on the information available to us as of the date of this presentation, are subject to change and are not guarantees of future performance. Forward‐looking statements involve risks, uncertainties and assumptions that are difficult to predict and could cause ViewRay’s results to differ materially from those presented. These risks, uncertainties and assumptions include, but are not limited to, changes in: the regulatory environment; global economics; trade compliance requirements, duties or tariffs; third‐party reimbursement levels; currency exchange rates; taxation, healthcare law, and product clearance requirements, as well as those related to: adverse publicity about ViewRay and our products; our reliance on sole or limited source suppliers; our ability to commercialize our products successfully; the impact of competitive products and pricing, and all other risks listed from time to time in the company’s filings with the Securities and Exchange Commission, which are incorporated into this Forward‐Looking Statements disclosure by this reference. We do not assume any obligation to update or revise the forward‐looking statements in ViewRay’s written or oral presentation, whether based on future events, new or additional information or otherwise. ViewRay’s written and oral presentation does not constitute an offer to sell or the solicitation of an offer to buy, securities. MEDICAL ADVICE DISCLAIMER ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary. 2

Cancer Treatment Moving to Personalized Care  3Cancer Treatment Moving to Personalized Care 3

Surgery 4 Right toSurgery 4 Right to

Medical Oncology 5Medical Oncology 5

MRIdian ‐ Defining a New Standard of Care in Radiation Oncology See. Shape. Strike. Size. 6MRIdian ‐ Defining a New Standard of Care in Radiation Oncology See. Shape. Strike. Size. 6

MRIdian: Pioneering Radiation Oncology Bibian Mentel • 3‐time Winter Paralympics  gold medalist • 5‐time world champion para‐ snowboarder • Battled cancer 9 times • Kicked cancer with MRIdian 7MRIdian: Pioneering Radiation Oncology Bibian Mentel • 3‐time Winter Paralympics gold medalist • 5‐time world champion para‐ snowboarder • Battled cancer 9 times • Kicked cancer with MRIdian 7

Clearly Differentiated Technology MRIdian Conventional Image Guided Radiation Therapy  Diagnostic‐Quality Imaging (IGRT)  Imaging  Images courtesy of Amsterdam UMC 8Clearly Differentiated Technology MRIdian Conventional Image Guided Radiation Therapy Diagnostic‐Quality Imaging (IGRT) Imaging Images courtesy of Amsterdam UMC 8

MRIdian vs. Traditional CT LINAC – Visibly Different MRIdian Market‐leading CT LINAC Images courtesy of the Siteman Cancer Center at Washington University School of Medicine 9MRIdian vs. Traditional CT LINAC – Visibly Different MRIdian Market‐leading CT LINAC Images courtesy of the Siteman Cancer Center at Washington University School of Medicine 9

Making the Invisible Visible “This would have been  unimaginable before  [MRIdian].” —M. Salim Saddiqui, MD  Director, Stereotactic Radiation Program Director, MR Simulation Program Department of Radiation Oncology Henry Ford Cancer Center Adaptive MR Image Guided Radiotherapy Symposium MR‐guided Radiation Therapy at the Henry Ford Cancer Institute: Making the  Invisible, Visible. Video courtesy of Henry Ford Health SystemMaking the Invisible Visible “This would have been unimaginable before [MRIdian].” —M. Salim Saddiqui, MD Director, Stereotactic Radiation Program Director, MR Simulation Program Department of Radiation Oncology Henry Ford Cancer Center Adaptive MR Image Guided Radiotherapy Symposium MR‐guided Radiation Therapy at the Henry Ford Cancer Institute: Making the Invisible, Visible. Video courtesy of Henry Ford Health System

Organ Motion Requires MRI Real‐Time, On‐Table Adaptive Esophagus/Other   video here Nice to have if can  located. TBD Images courtesy of Henke et al. Int J Radiation Oncol Bio PhysOrgan Motion Requires MRI Real‐Time, On‐Table Adaptive Esophagus/Other video here Nice to have if can located. TBD Images courtesy of Henke et al. Int J Radiation Oncol Bio Phys

Conventional CT vs. MRIdian…the difference is clear 12Conventional CT vs. MRIdian…the difference is clear 12

Key Opinion Leader Perspective “Just as the two‐dimensional x‐rays we relied on in  the 1980s were replaced by CT‐guided radiotherapy,  so will MR‐guided radiation technology render  CT‐guided radiation obsolete. —Daphne A. Haas‐Kogan, MD Chair of the Department of Radiation Oncology at Dana‐Farber Cancer Institute,  Brigham and Women's Hospital and Boston Children's Hospital “Opportunities Abound for Radiation Oncology in the Era of Personalized Medicine.” RSNA Daily Bulletin. November  2017 13Key Opinion Leader Perspective “Just as the two‐dimensional x‐rays we relied on in the 1980s were replaced by CT‐guided radiotherapy, so will MR‐guided radiation technology render CT‐guided radiation obsolete. —Daphne A. Haas‐Kogan, MD Chair of the Department of Radiation Oncology at Dana‐Farber Cancer Institute, Brigham and Women's Hospital and Boston Children's Hospital “Opportunities Abound for Radiation Oncology in the Era of Personalized Medicine.” RSNA Daily Bulletin. November 2017 13

Re‐envisioning Radiation Therapy: The Future is Now   Other MRgRT  Conventional  MRIdian Technologies IGRT LINACs — See.üü —— Shape. ü —— Strike. ü — Size. üü 14Re‐envisioning Radiation Therapy: The Future is Now Other MRgRT Conventional MRIdian Technologies IGRT LINACs — See.üü —— Shape. ü —— Strike. ü — Size. üü 14

MR Linac: a Niche or Emerging Standard of Care? All patients require precision, and ~80% of the time the use of MRIdian will  likely enhance treatment outcomes. ‐ Dr. Michael Steinberg, UCLAMR Linac: a Niche or Emerging Standard of Care? All patients require precision, and ~80% of the time the use of MRIdian will likely enhance treatment outcomes. ‐ Dr. Michael Steinberg, UCLA

Big Benefits for Hospitals, Physicians and Patients áThroughput Capacity áReimbursement and  Economics áAccess to CareBig Benefits for Hospitals, Physicians and Patients áThroughput Capacity áReimbursement and Economics áAccess to Care

Driving Adoption in a Large, Underserved Market $6.3B  $4.6B  Global radiotherapy market in 2015 Projected Global  Radiotherapy Market  in 2020 Markets & Markets, 2015 Radiotherapy Market Global Forecasts 2020Driving Adoption in a Large, Underserved Market $6.3B $4.6B Global radiotherapy market in 2015 Projected Global Radiotherapy Market in 2020 Markets & Markets, 2015 Radiotherapy Market Global Forecasts 2020

How We Win Commercial  Operational  Organization Excellence Therapy Adoption via  Customer  Innovation, Clinical  Service Data, & Training 18How We Win Commercial Operational Organization Excellence Therapy Adoption via Customer Innovation, Clinical Service Data, & Training 18

Bold Commercial Strategy Providing access and serving more patients  • Building commercial team, distribution network • Initial focus on United States, EMEA and Japan • This is ~70% of market opportunity Markets & Markets, 2015 Radiotherapy Market Global Forecasts 2020Bold Commercial Strategy Providing access and serving more patients • Building commercial team, distribution network • Initial focus on United States, EMEA and Japan • This is ~70% of market opportunity Markets & Markets, 2015 Radiotherapy Market Global Forecasts 2020

Relentless Focus on Operational Excellence  Driving efficiency across the organization • Purchase order to rev rec goal: of 6 to 4 quarters • Vault readiness • Manufacturing efficiencies, supply chain managementRelentless Focus on Operational Excellence Driving efficiency across the organization • Purchase order to rev rec goal: of 6 to 4 quarters • Vault readiness • Manufacturing efficiencies, supply chain management

Customer Service Radical customer delight • World‐class service and support • Clinical workflow • Innovation, clinical data and  training 21Customer Service Radical customer delight • World‐class service and support • Clinical workflow • Innovation, clinical data and training 21

Therapy Adoption:  Game‐changing Technological Innovation Extending our leadership position • Speed, machine vision, biologic imaging • “Groundbreaking” long‐term pipeline • 2 advancements planned in FY’19 • Strong intellectual property portfolio 22Therapy Adoption: Game‐changing Technological Innovation Extending our leadership position • Speed, machine vision, biologic imaging • “Groundbreaking” long‐term pipeline • 2 advancements planned in FY’19 • Strong intellectual property portfolio 22

Therapy Adoption: Early, Compelling Data • Increase in Overall Survival with simultaneous vanishing of  1,2,3,4 Grade 3+ Toxicity in unresectable pancreatic cancer • Ability to treat prostate with very high doses in few sessions  5 with very low toxicity [new ASTRO, AUA, ASCO guidelines] • Ability to treat partial breast with very high doses in few  6,7,8,9,10 sessions with excellent cosmesis 11 • 50% less treatment volumes in whole breast • Many more examples in lung, liver, oligomets in the abdomen,  adrenal tumors, etc. See citations in appendix included at end of presentation  23Therapy Adoption: Early, Compelling Data • Increase in Overall Survival with simultaneous vanishing of 1,2,3,4 Grade 3+ Toxicity in unresectable pancreatic cancer • Ability to treat prostate with very high doses in few sessions 5 with very low toxicity [new ASTRO, AUA, ASCO guidelines] • Ability to treat partial breast with very high doses in few 6,7,8,9,10 sessions with excellent cosmesis 11 • 50% less treatment volumes in whole breast • Many more examples in lung, liver, oligomets in the abdomen, adrenal tumors, etc. See citations in appendix included at end of presentation 23

Therapy Adoption:  Current and Desired State Early Adopter: VUMC in Amsterdam • Almost 100% MRIdian treatments adaptive • About 100% hypofractionated treatments • Compelling outcomes 24Therapy Adoption: Current and Desired State Early Adopter: VUMC in Amsterdam • Almost 100% MRIdian treatments adaptive • About 100% hypofractionated treatments • Compelling outcomes 24

Preliminary Fourth Quarter and Full Year 2018 Results Q4 Results • Total revenue of ~$21 million, primarily from 3 revenue units and 1 upgrade • Received 8 new orders for MRIdian systems totaling approximately $49 million • Backlog was approximately $212 million as of December 31, 2018 • Cash and cash equivalents approximately $167 million as of December 31, 2018 Full Year Results • Total revenue of approximately $81 millionPreliminary Fourth Quarter and Full Year 2018 Results Q4 Results • Total revenue of ~$21 million, primarily from 3 revenue units and 1 upgrade • Received 8 new orders for MRIdian systems totaling approximately $49 million • Backlog was approximately $212 million as of December 31, 2018 • Cash and cash equivalents approximately $167 million as of December 31, 2018 Full Year Results • Total revenue of approximately $81 million

Growth Profile  ~99% revenue CAGR since 2015 90 60 30 0 2015 2016 2017 2018 Preliminary Results Source: Company filings In millions of $Growth Profile ~99% revenue CAGR since 2015 90 60 30 0 2015 2016 2017 2018 Preliminary Results Source: Company filings In millions of $

How We Win Creating shareholder Value • Big market opportunity • Aligned view on MR technology • MRIdian enables trend toward precise,  personalized therapy Customer  Commercial  Readiness and  • Investing in innovation, clinical data,  Organization Installations training, and infrastructure Therapy Adoption via  Customer  Innovation, Clinical Data  Service and Training 27How We Win Creating shareholder Value • Big market opportunity • Aligned view on MR technology • MRIdian enables trend toward precise, personalized therapy Customer Commercial Readiness and • Investing in innovation, clinical data, Organization Installations training, and infrastructure Therapy Adoption via Customer Innovation, Clinical Data Service and Training 27

A Giant Leap in Cancer Therapy Innovation J.P. Morgan Healthcare Conference January 2019 A Giant Leap in Cancer Therapy Innovation J.P. Morgan Healthcare Conference January 2019

J.P. Morgan Healthcare Conference January 2019J.P. Morgan Healthcare Conference January 2019

Appendix 1 Dr. Henke, ASTRO 2018, https://vimeo.com/298626732#t=458 2  Dr. Bassetti, Miami Symposium 2018, https://vimeo.com/293472071#t=1224 3  Dr. Parikh ASTRO 2017 Abstract, ASTRO 2017 multi‐institutional, https://www.redjournal.org/article/S0360‐ 3016(17)32096‐5/fulltext 4  Washington University, Abstract from ASTRO 2018, https://www.redjournal.org/article/S0360‐3016(18)31888‐ 1/fulltext 5  Dr. Ben Slotman, Amsterdam Symposium March 2018, https://vimeo.com/264778067#t=145 6  Dr. Zoberi, Washington University School of Medicine, ASTRO 2018, https://vimeo.com/300878157#t=980 7  ASTRO Abstract 2018 – single fraction, https://www.redjournal.org/article/S0360‐3016(18)31564‐5/fulltext 8  ASTRO Abstract 2017 – single fraction, https://www.redjournal.org/article/S0360‐3016(17)31788‐1/fulltext 9  ASTRO 2016 Abstract – APBI 10 FX BID, https://www.redjournal.org/article/S0360‐3016(16)31037‐9/fulltext 10  Red Journal Manuscript, https://www.redjournal.org/article/S0360‐3016(16)33065‐6/abstract 11  Dr. Zoberi, Washington University School of Medicine, ASTRO 2018, https://vimeo.com/300878157#t=860 30Appendix 1 Dr. Henke, ASTRO 2018, https://vimeo.com/298626732#t=458 2 Dr. Bassetti, Miami Symposium 2018, https://vimeo.com/293472071#t=1224 3 Dr. Parikh ASTRO 2017 Abstract, ASTRO 2017 multi‐institutional, https://www.redjournal.org/article/S0360‐ 3016(17)32096‐5/fulltext 4 Washington University, Abstract from ASTRO 2018, https://www.redjournal.org/article/S0360‐3016(18)31888‐ 1/fulltext 5 Dr. Ben Slotman, Amsterdam Symposium March 2018, https://vimeo.com/264778067#t=145 6 Dr. Zoberi, Washington University School of Medicine, ASTRO 2018, https://vimeo.com/300878157#t=980 7 ASTRO Abstract 2018 – single fraction, https://www.redjournal.org/article/S0360‐3016(18)31564‐5/fulltext 8 ASTRO Abstract 2017 – single fraction, https://www.redjournal.org/article/S0360‐3016(17)31788‐1/fulltext 9 ASTRO 2016 Abstract – APBI 10 FX BID, https://www.redjournal.org/article/S0360‐3016(16)31037‐9/fulltext 10 Red Journal Manuscript, https://www.redjournal.org/article/S0360‐3016(16)33065‐6/abstract 11 Dr. Zoberi, Washington University School of Medicine, ASTRO 2018, https://vimeo.com/300878157#t=860 30